Kyowa Kirin Co Ltd represents a set of core values and corporate philosophy. The company prioritizes the health and well-being of patients, aiming to contribute to the advancement of medical science and enhance the quality of life. Kyowa Kirin Co Ltd focuses on innovation, putting patient needs at the forefront of its research and development activities. The company believes in collaboration and partnerships to drive progress in delivering novel therapies and addressing unmet medical needs. With a commitment to integrity and ethical business practices, Kyowa Kirin Co Ltd strives to make a positive impact and improve the lives of patients worldwide.

Kyowa Kirin Co Ltd is primarily present in Japan, where it is headquartered. Additionally, the company has a significant presence in other countries and regions worldwide. These include the United States, where it operates through a subsidiary, as well as various regions in Europe, including the United Kingdom, Germany, France, and Switzerland. With a global reach and a strong presence in multiple markets, Kyowa Kirin Co Ltd is able to leverage its expertise and product offerings across different regions to optimize its business operations and serve a diverse customer base effectively.

Kyowa Kirin Co Ltd, a leading pharmaceutical company, has achieved noteworthy milestones over the years. Notably, the company successfully developed and launched several groundbreaking medicines, such as Poteligeo, a treatment for skin conditions like cutaneous T-cell lymphoma. Additionally, Kyowa Kirin Co Ltd secured regulatory approvals for novel therapies like CRYSVITA, a treatment for rare bone diseases. Furthermore, the company built strategic alliances and partnerships to expand its global footprint and enhance research capabilities. In recent years, Kyowa Kirin Co Ltd has shown a strong commitment to innovation and patient care, continuously striving to improve the lives of individuals worldwide through its breakthrough advancements.

Kyowa Kirin Co Ltd, formerly known as Kyowa Hakko Kirin Co Ltd, is a leading Japanese pharmaceutical company. Founded in 1949, it has a rich history and background in the healthcare sector. Kyowa Kirin specializes in the research, development, manufacturing, and marketing of innovative and life-saving pharmaceuticals. Over the years, the company has been dedicated to delivering high-quality medicines for a wide range of diseases, including cancer, renal diseases, and immune disorders. With a strong emphasis on scientific research and technological advancements, Kyowa Kirin has established itself as a trusted and reliable name in the global pharmaceutical industry.

The main competitors of Kyowa Kirin Co Ltd in the market include other pharmaceutical and biotechnology companies such as Takeda Pharmaceutical Company Limited, Eisai Co Ltd, and Astellas Pharma Inc. These companies also operate in the healthcare sector, developing and selling various drugs and therapies. Kyowa Kirin Co Ltd competes with these companies in terms of research and development, product pipelines, market share, and global presence.

Kyowa Kirin Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

The business model of Kyowa Kirin Co Ltd is focused on the development, manufacturing, and commercialization of specialty pharmaceuticals. The company primarily operates in the fields of nephrology, oncology, and immunology. Kyowa Kirin Co Ltd strives to bring innovative and high-quality therapeutic solutions to patients worldwide. With a strong commitment to research and development, the company invests in advancements in biotechnology and strives to address unmet medical needs. Kyowa Kirin Co Ltd also collaborates with global partners to expand its product portfolio and reach a wider patient population, all while maintaining a strong focus on patient-centricity and improving healthcare outcomes.

The Kyowa Kirin Co P/E ratio is 16.22.

The Kyowa Kirin Co P/S ratio is 2.25.

The Quality Investing for Kyowa Kirin Co is 6/10.

The expected Kyowa Kirin Co revenue is 502.38 B JPY.

The expected Kyowa Kirin Co profit is 69.75 B JPY.

Kyowa Kirin Co Ltd is a global pharmaceutical company based in Japan that focuses on the development, manufacturing, and marketing of medications for patients with rare diseases. The company's business operations are divided into four segments: 1. Pharmaceutical Business: Kyowa Kirin focuses on researching and developing innovative medications for patients with rare diseases or unmet medical needs. The portfolio includes treatments for diseases such as kidney diseases, cancer, blood disorders, immunological diseases, neurological diseases, and heart diseases. 2. Bio-Chemicals Business: Kyowa Kirin produces biochemical products for biotech companies and research institutions worldwide. The company is capable of manufacturing a wide range of biochemicals, enzymes, reagents, and active ingredients at the highest level. 3. Vaccines Business: Kyowa Kirin focuses on developing vaccines against life-threatening diseases in this segment. Kyowa Kirin's experts have decades of experience in vaccine development, significantly supporting the containment of infectious diseases. 4. Renal Diseases Business: The Renal Diseases Business segment provides innovative solutions for patients with kidney diseases. This target group includes particularly patients suffering from life-threatening chronic kidney diseases and in need of a kidney transplant. In this context, the product "Nesp" (Darbepoetin alfa) was developed to stimulate erythropoietin production, which promotes the formation of red blood cells. Kyowa Kirin Co Ltd is committed to improving lives and developing life-saving treatments for patients. The company employs a highly diversified business strategy. The aim is to increase the profitability of each business segment by combining the company's strengths in areas such as drug development, analysis and synthesis technology, clinical trials, production, and distribution. As a leading pharmaceutical company, Kyowa Kirin Co Ltd strives to continuously provide high-quality services to patients. To achieve this, the company collaborates closely with partners from the scientific and industrial sectors, as well as patient organizations worldwide. Kyowa Kirin also aims to act responsibly and integrate sustainable practices into all aspects of its business.

Kyowa Kirin Co pays a dividend of 51 JPY distributed over payouts per year.

The dividend cannot currently be calculated for Kyowa Kirin Co or the company does not pay out a dividend.

The ISIN of Kyowa Kirin Co is JP3256000005.

The WKN of Kyowa Kirin Co is 858523.

The ticker of Kyowa Kirin Co is 4151.T.

Over the past 12 months, Kyowa Kirin Co paid a dividend of 58 JPY . This corresponds to a dividend yield of about 2.71 %. For the coming 12 months, Kyowa Kirin Co is expected to pay a dividend of 60.05 JPY.

The current dividend yield of Kyowa Kirin Co is 2.71 %.

Kyowa Kirin Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

Kyowa Kirin Co paid dividends every year for the past 23 years.

For the upcoming 12 months, dividends amounting to 60.05 JPY are expected. This corresponds to a dividend yield of 2.81 %.

Kyowa Kirin Co is assigned to the 'Health' sector.

To receive the latest dividend of Kyowa Kirin Co from 3/1/2025 amounting to 29 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

The last dividend was paid out on 3/1/2025.

In the year 2024, Kyowa Kirin Co distributed 56 JPY as dividends.

The dividends of Kyowa Kirin Co are distributed in JPY.